This study presents the design and evaluation of a plant-based bio-battery, specifically a plant microbial fuel cell (plant-MFC), utilizing peppermint plants and monitored by an open-source electronic system. The goal was to develop a sustainable, low-cost bioenergy solution by integrating plant-MFCs into clay pots and equipping them with an Arduino-based monitoring system. This system features an OLED display, capacitive soil moisture sensors, and data logging capabilities via a microSD card. Four plant-MFCs were constructed and tested over 30 days. Voltage and soil moisture data were recorded every 10 minutes, and polarization experiments were conducted to assess power output. The results demonstrated consistent open-circuit voltages averaging 1.1 V, with peaks reaching 1.2 V. The maximum power densities achieved were 645.91 mW/m³, indicating the effectiveness of the design. The system's performance highlights the importance of soil moisture and plant health in maximizing energy generation. Its open-source nature allows for easy replication and modification, making it suitable for educational purposes and encouraging collaboration within scientific and maker communities. This interdisciplinary approach, which merges biology, electronics, and renewable energy, demonstrates the potential of plant-MFCs for off-grid power generation, environmental monitoring, and science education. The findings contribute to ongoing efforts to develop accessible and sustainable bioelectrochemical energy technologies.
Background and Aims: MicroRNA‐1246 (miR‐1246) has emerged as an important regulatory molecule in breast cancer, with growing evidence supporting its role in diagnosis, prognosis, and therapeutic response. This review aims to evaluate the diagnostic, prognostic, and therapeutic significance of miR‐1246 in breast cancer and to assess its potential pharmacoeconomic impact on clinical practice. Methods: A narrative review was conducted using a structured literature search of PubMed, Scopus, and Web of Science databases. Study identification and selection were informed by PRISMA screening principles to enhance transparency and reproducibility; however, this review was not conducted as a formal systematic review or meta‐analysis. Studies investigating miR‐1246 expression patterns, associations with clinicopathological features, patient outcomes, therapeutic responses, and pharmacoeconomic aspects, including cost‐effectiveness of diagnostic and therapeutic applications, were included. Results: Elevated miR‐1246 expression was consistently associated with aggressive breast cancer phenotypes, particularly triple‐negative breast cancer (TNBC), and poorer clinical outcomes. Several studies demonstrated that targeting miR‐1246 enhances the efficacy of hormone therapy and immunotherapy, suggesting a role in overcoming treatment resistance. Pharmacoeconomic evaluations indicated that integrating miR‐1246 into diagnostic and therapeutic strategies may have the potential to be cost‐effective, provided that future economic evaluations confirm improvements in early detection and treatment selection. Conclusion: miR‐1246 shows strong potential as a diagnostic and prognostic biomarker and as a therapeutic target in breast cancer. Despite promising findings, further clinical validation and standardized integration into routine practice are required to fully establish its clinical and economic value.
8 July 2025 in International Journal of Genetics and Genomics
Background: The pathophysiology of Prostate Cancer (PCa) involves a complex interplay of environmental and genetic factors. PCa diagnosis faces challenges of false-positive outcomes, emphasizing the necessity for revising the available screening methods for PCa. Single-nucleotide polymorphisms (SNPs) have been linked with PCa and constitute a key risk factor in prostate carcinogenesis. Objective: This research aimed at examining the association between susceptibility to PCa and polymorphisms of the Leptin (LEP) gene -2548 G˃A (rs7799039) and LEP receptor (LEPR) gene 223 A˃G (rs1137101). Methods: A total of 66 patients and 34 controls of a Jordanian population were recruited. DNA was isolated from blood leucocytes. Polymorphism analyses were performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approaches. Results: The mutant allele (A) and genotype (AA) frequencies of the LEP SNP (-2548 G˃A, rs7799039) were significantly higher in the PCa patients (59.1% and 37.9%, respectively) compared to those in the control group (45.6% and 20.6%, respectively) (P = 0.039; OR = 1.88, 95%CI = 1.02 - 2.89 and P = 0.043; OR = 2.86, 95%CI = 1.77 - 5.92, respectively). This indicates that this SNP was associated with an overall increased risk of PCa. In contrast, the LEPR 223 A˃G was not. Further stratification of the PCa group showed that the incidence of both SNPs was correlated with high serum PSA levels and metastasis risk. The results with age and Gleason biopsy score were not conclusive because the trend observed did not reach significance. Conclusions: The findings support our hypothesis regarding the association of the polymorphism in the LEP gene in prostate carcinogenesis (the A and AA frequencies, compared with the control, were associated with a 1.3-fold and a 1.8-fold increased risk for PCa, respectively. However, there was no association between the LEPR (rs1137101) gene variant and PCa risk.
Background: Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, often associated with poor prognosis and resistance to treatment. The Epidermal Growth Factor Receptor (EGFR) remains a crucial target in therapy. Methods: An advanced computational workflow was used to identify and optimize EGFR inhibitors, integrating active site prediction (CB-Dock2), ligand generation (Lead3), virtual screening (AutoDock Vina), ADMET analysis (ADMETlab 2.0), and QSAR modeling. The QSAR model was validated to ensure predictive reliability. Results: Compound g18_mol18 demonstrated a binding affinity of -9.9 kcal/mol, significantly stronger than the standard compound (-7.381 kcal/mol) (p = 0.039). Interaction analysis showed that g18_mol18 formed multiple hydrogen bonds and hydrophobic contacts with key residues. Despite its strong binding affinity, ADMET analysis highlighted challenges such as poor intestinal absorption (HIA: 0.005) and potential hepatotoxicity. However, its low hERG inhibition (0.302 vs. 0.923) indicates a lower risk of cardiotoxicity, suggesting a favorable cardiac safety profile. Conclusion: The study identifies g18_mol18 as a potent EGFR inhibitor with significantly higher binding affinity and more extensive interactions than current treatments. Although it presents pharmacokinetic challenges, these findings underline its potential as a more effective and safer alternative for NSCLC treatment, warranting further experimental validation and optimization for clinical applications. Such developments could lead to durable therapeutic responses, addressing key resistance issues seen with current EGFR inhibitors.